-
EnteroMedics Inc (NASDAQ: ETRM) shares surged
73.3 percent to $6.88. EnteroMedics shares have jumped 120.56 percent over the past 52 weeks, while the S&P 500 index has
gained 14.01 percent in the same period.
-
SunLink Health Systems, Inc. (NYSE: SSY) shares
jumped 30.4 percent to $1.46. SunLink Health announced plans to buyback 3 million shares at $1.50 per share.
-
Zafgen Inc (NASDAQ: ZFGN) shares jumped 21.2
percent to $4.06g after gaining 0.60 percent on Thursday.
-
Quotient Ltd (NASDAQ: QTNT) shares gained 16.7
percent to $6.29 after the company reported positive MosaiQ results from its performance evaluation study.
-
Stemline Therapeutics Inc (NASDAQ: STML) shares
climbed 14.2 percent to $12.96 after the company reported a FDA deal on expedited pathway to full approval of SL-401 in
first-line BPDCN.
-
Pacira Pharmaceuticals Inc (NASDAQ: PCRX) shares
surged 14.2 percent to $39.00. Pacira Pharmaceuticals reported preliminary 2016 revenue of $276.4 million.
-
Cempra Inc (NASDAQ: CEMP) shares gained 12.3
percent to $3.65.
-
Abeona Therapeutics Inc (NASDAQ: ABEO) climbed
6.7 percent to $5.97. Jefferies initiated coverage on Abeona Therapeutics with a Buy rating.
-
Healthways, Inc. (NASDAQ: HWAY) shares rose 6.5
percent to $24.75. Jefferies upgraded Healthways from Hold to Buy.
-
Helen of Troy Limited (NASDAQ: HELE) shares
climbed 6.4 percent to $95.00. Helen of Troy reported better-than-expected earnings for its third quarter, but sales missed
expectations. The company raised its earnings forecast for the year, but lowered its sales outlook.
-
Ionis Pharmaceuticals Inc (NASDAQ: IONS) shares
gained 5.5 percent to $49.66 after the company reported a licensing deal with Novartis AG (ADR) (NYSE: NVS).
-
CTI BioPharma Corp (NASDAQ: CTIC) shares rose 4.5
percent to $4.66 after surging 12.34 percent on Thursday.
-
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
shares rose 4.4 percent to $43.19. Neurocrine issued an update on FDA Advisory Committee for INGREZZA for the treatment of
tardive dyskinesia.
-
Amgen, Inc. (NASDAQ: AMGN) rose 3.3 percent to
$157.96 after the company disclosed that it has won a court ruling for a ban on Sanofi's sales of praluent cholestrol drug.
-
Gap Inc (NYSE: GPS) rose 2.4 percent to $23.80. Gap
reported a 2 percent year-over-year gain in its comparable sales for the November and December 2016 holiday season. Gap
comparable sales for December rose 4 percent, compared to a 5 percent decline last year.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.